Skip to main content

Table 3 Secondary outcomes: SF-36 change scores from baseline to end of studya

From: Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden

RAND SF-36 Control group (n = 24) MTM group (n = 25) p value
Health domains
 General health –3.9 ± 14.9 4.3 ± 13.8 0.06
 Physical functioning 3.6 ± 16.0 –5.2 ± 15.6 0.06
 Bodily pain 1.8 ± 31.5 –6.8 ± 20.8 0.28
 Role limitations, physical 4.6 ± 41.3 1.0 ± 32.5 0.75
 Mental health –6.1 ± 12.7 4.8 ± 12.5 0.005
 Vitality –4.9 ± 16.3 2.8 ± 12.9 0.08
 Social functioning –1.7 ± 29.2 0.5 ± 20.6 0.76
 Role limitation, emotional –6.1 ± 31.9 0.0 ± 32.6 0.53
Component scores
 Physical health 1.5 ± 16.5 –1.2 ± 13.2 0.53
 Mental health –4.7 ± 14.0 2.1 ± 12.9 0.09
  1. Data presented as mean ± SD or N (%)
  2. MTM medication therapy management, SF-36 Short Form Health Survey
  3. aA negative result means a worsening on the measure between baseline and the end-of-study visit